Forum Topic News
  • Conversation: Novartis' migraine drug gets EMA approval

    • July 31, 2018 1:47 PM BST
      • Post(s)
        549

      Novartis' migraine drug gets EMA approval

      The EMA has approved Norvartis’ Aimovig (erenumab), making it Europe’s first treatment specifically designed to prevent migraine.
      The drug works by blocking the calcitonin gene-related peptide (CGRP) receptor, thought to be involved in the transmission of the pain signals associated with migraine.
      Migraine is a complex and debilitating neurological condition that affects each individual differently. Over 610,000 people in the UK are estimated to experience chronic migraine, with the 2010 Equality Act classing migraine as a disability should the condition have a long term, substantial impact on day to day or work-related activities.
      Read more: http://www.pharmatimes.com/news/novartis_migraine_drug_gets_ema_approval_1246290

Add Reputation

Do you want to add reputation for this member by this post?

or cancel